Precision Medicine

Theranostic Modulations Push the Cancer-Treatment Envelope

Intratumoral distribution and retention of theranostic particles can be improved by controlling protein adsorption to advance cancer management

dM_Gold_Nanoparticles_main.jpg
A major challenge in tumor treatment is the lack of homogenous drug distribution within the tumor mass. Nanomedicine involving direct administration of nanomaterials into the bloodstream has the advantage of accelerated distribution within the bloodstream with the concomitant pitfall of expeditious clearance by the kidney, spleen, and liver. Carly Filgueira, PhD, assistant professor of nanomedicine and cardiovascular surgery at Houston Methodist circumvented this challenge by intratumoral injections of highly concentrated nanoformulations and demonstrated a nine-day retention without significant accumulation in other organs.
CarlyProPhotoForNelson.jpg
Carly Filgueira, PhD, assistant professor of nanomedicine
Specifically, Filgueira investigated the biodistribution and retention of passivated gold nanoparticles in an in vivo murine model of non-small cell lung cancer (NSCLC). Study results using computed tomography and inductively coupled plasma optical emission spectrometry (published in Pharmaceutics in 2021), demonstrated that surface passivation of the gold nanoparticles determines the extent of their cellular uptake and intratumoral distribution. Nanoformulations carrying drugs can increase the efficacy of treatment by enhancing tumor exposure to the therapeutic agent. Refining these strategies for controlling and optimizing the surface passivation of nanoparticles to further enhance tumor uptake and distribution will push the envelope on successful cancer treatment.
Rossana Terracciano, Aobo Zhang, E Brian Butler, Danilo Demarchi, Jason H Hafner, Alessandro Grattoni, Carly S Filgueira. Effects of Surface Protein Adsorption on the Distribution and Retention of Intratumorally Administered Gold Nanoparticles. Pharmaceutics. 2021 Feb 5;13(2):216. doi: 10.3390/pharmaceutics13020216. This research was funded by collaborative seed funding from Rice University and the Houston Methodist Research Institute (J.H.H. and C.S.F.), Golfers Against Cancer (A.G., E.B.B. and C.S.F.), and funds from Houston Methodist Research Institute (C.S.F.).
Abanti Chattopadhyay, PhD
October 2022
Share this story
Facebook.svg
Twitter.svg
Linkedin.svg
Follow us
Copyright 2022. Houston Methodist, Houston, TX. All rights reserved.
Click to scroll back to the topClick to go to previous articleClick to go to next article
Close.svg
result
Share this story
Facebook.svg
Twitter.svg
Linkedin.svg